

## UTILIZATION MANAGEMENT MEDICAL POLICY

**POLICY:** Iron Replacement – Ferumoxytol Utilization Management Medical Policy

- Feraheme® (ferumoxytol intravenous infusion – AMAG, generic)

**REVIEW DATE:** 01/07/2026

---

### OVERVIEW

Ferumoxytol (Feraheme, generic), an intravenous iron replacement product, is indicated for the treatment of **iron deficiency anemia** in patients  $\geq 18$  years of age for the following uses:<sup>1</sup>

- **Chronic kidney disease (CKD).**
- **Intolerance to oral iron or have had unsatisfactory response to oral iron.**

### Dosing Information

Ferumoxytol is administered by intravenous (IV) infusion and treatment may be repeated if iron deficiency remains persistent or recurring.<sup>1</sup> The dosage of ferumoxytol is expressed in terms of mg of elemental iron, with each mL containing 30 mg of elemental iron. The recommended dose of ferumoxytol is an initial 510 mg dose followed by a second 510 mg dose 3 to 8 days later per treatment cycle.

### Guidelines

#### *Anemia in CKD*

The Kidney Disease: Improving Global Outcomes clinical practice guideline for anemia in CKD (2025) make various recommendations regarding iron therapy.<sup>2</sup> For patients with CKD and anemia receiving hemodialysis, initiation of IV iron is suggested if transferrin saturation (TSAT) is  $\leq 30\%$  and ferritin is  $\leq 500$  ng/mL. For patients with CKD and anemia who are not receiving hemodialysis or treated with peritoneal dialysis, initiation of oral or IV iron is suggested if TSAT is  $< 40\%$  and ferritin  $< 100$  ng/mL or if TSAT  $< 25\%$  with ferritin  $\geq 100$  ng/mL and  $< 300$  ng/mL. For patients with CKD and profound iron deficiency (TSAT  $< 20\%$  and ferritin  $< 30$  ng/mL) but no anemia, consider treatment with oral or IV iron. Additional practice points are noted such as a switch from oral to IV iron if there is an insufficient effect of an optimal oral regimen after 1 to 3 months. KDIGO also notes the choice between different formulations of IV iron should be guided by individual considerations and recommended dosing schedules.

#### *Cancer-Related Anemia*

The National Comprehensive Cancer Network guidelines on hematopoietic growth factors (version 3.2026 – December 5, 2025) discuss the management of cancer- and chemotherapy-induced anemia.<sup>3</sup> Treatment for iron deficiency is guided by iron status, which is defined in the guidelines as: absolute iron deficiency, functional iron deficiency, possible functional iron deficiency, or no iron deficiency, and use in combination with erythropoiesis-stimulating agents (ESAs). IV iron therapy is considered an option for patients with absolute iron deficiency (ferritin  $< 30$  ng/mL and TSAT  $< 20\%$ ) and possible functional iron deficiency (ferritin  $> 500$ - $800$  ng/mL and TSAT  $< 50\%$ ) in selected patients (with the goal of avoiding allogeneic transfusion). IV iron therapy is also considered an option in combination with ESAs for the treatment of functional iron deficiency (ferritin 30 to 500 ng/mL and TSAT  $< 50\%$ ) in patients receiving myelosuppressive chemotherapy without curative intent and absolute iron deficiency (ferritin  $< 30$  ng/mL and TSAT  $< 20\%$ ) in patients who do not experience an increase in hemoglobin after four weeks of IV or oral iron supplementation. All recommendations are category 2A for each product.

01/07/2026

© 2026. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

### *Heart Failure*

The American College of Cardiology/American Heart Association guideline for the management of heart failure (2022) states that in patients with heart failure with reduced ejection fraction (left ventricular ejection fraction  $\leq 40\%$ ), absolute iron deficiency (ferritin  $< 100$  ng/mL) or functional iron deficiency (ferritin = 100 to 300 mg/mL if TSAT is  $< 20\%$ ), and with or without anemia, IV iron replacement is reasonable to improve functional status and quality of life (2a recommendation).<sup>4</sup>

### **Safety**

Ferumoxytol has a black box warning regarding the risk for fatal and serious hypersensitivity reactions including anaphylaxis.<sup>1</sup>

### **POLICY STATEMENT**

Prior Authorization is recommended for medical benefit coverage of ferumoxytol. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indications. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with ferumoxytol as well as the monitoring required for adverse events and long-term efficacy, particular approvals require ferumoxytol to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Automation:** None.

### **RECOMMENDED AUTHORIZATION CRITERIA**

Coverage of ferumoxytol is recommended in those who meet one of the following criteria:

#### **FDA-Approved Indications**

---

**1. Iron Deficiency Anemia in Patients with Chronic Kidney Disease who are on Dialysis.** Approve for 3 years.

---

**2. Iron Deficiency Anemia in Patients with Chronic Kidney Disease who are not on Dialysis.** Approve for 1 year if the patient meets BOTH of the following (A and B):

- A)** Patient is  $\geq 18$  years of age; AND
- B)** The medication is prescribed by or in consultation with a nephrologist or hematologist.

**Dosing.** Approve up to a maximum cumulative total dose of 1020 mg given intravenously per 30 days.

---

**3. Iron Deficiency Anemia, Other.** Approve for 1 year if the patient meets BOTH of the following (A and B):

- A)** Patient is  $\geq 18$  years of age; AND
- B)** Patient meets ONE of the following (i, ii, iii, or iv):
  - i.** Patient meets BOTH of the following (a and b):
    - a)** Patient has tried oral iron supplementation; AND
    - b)** According to the prescriber, oral iron supplementation was ineffective or intolerable; OR

- ii. According to the prescriber, patient has a condition that will interfere with oral iron absorption;  
OR

Note: Examples of conditions that may interfere with oral iron absorption may include inflammatory bowel disease such as Crohn’s disease or ulcerative colitis.

- iii. Patient is currently receiving an erythropoiesis-stimulating agent; OR

Note: Examples of erythropoiesis-stimulating agents include an epoetin alfa product, a darbepoetin alfa product, or a methoxy polyethylene glycol-epoetin beta product.

- iv. The medication is being requested for cancer- or chemotherapy-related anemia.

**Dosing.** Approve up to a maximum cumulative total dose of 1020 mg given intravenously per 30 days.

### Other Uses with Supportive Evidence

- 
- 4. **Iron Deficiency Associated with Heart Failure.** Approve for 1 year if the patient meets BOTH of the following (A and B):

A) Patient is  $\geq$  18 years of age; AND

B) The medication is being prescribed by or in consultation with a cardiologist or hematologist.

**Dosing.** Approve up to a maximum cumulative total dose of 1020 mg given intravenously per 30 days.

---

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of ferumoxytol is not recommended in the following situations:

- 1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### REFERENCES

1. Feraheme® [prescribing information]. Waltham, MA: AMAG; June 2022.
2. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. 2025 KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease (*November 2024 Public Review Draft*). Available at: <https://kdigo.org/guidelines/anemia-in-ckd/>. Accessed on December 15, 2025.
3. The NCCN Hematopoietic Growth Factors Guidelines in Oncology (version 3.2026 – December 5, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on December 16, 2025.
4. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in *J Am Coll Cardiol*. 2023 Apr 18;81(15):1551]. *J Am Coll Cardiol*. 2022;79(17):e263-e421.

**HISTORY**

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes	01/10/2024
Annual Revision	<b>Iron Deficiency Anemia, Other:</b> The verbiage “patient has a condition which, per the prescriber, will interfere with oral iron absorption” was updated to “according to the prescriber, patient has a condition that will interfere with oral iron absorption”. Examples of “conditions that may interfere with oral iron absorption” were moved from the criteria to a Note. The term “erythroid-stimulating agents” was updated to “erythropoiesis-stimulating agents”.	01/15/2025
Annual Revision	The name of the policy was changed from <i>Iron Replacement – Feraheme</i> to as listed. Throughout the policy, reference to “Feraheme” was changed to “ferumoxytol”.	01/07/2026